Navigation Links
HeartWare Announces Presentations at The International Society of Heart and Lung Transplantation Annual Meeting
Date:4/12/2011

ional customers in 18 countries, as well as 41 U.S. clinical sites actively screening patients for our ENDURANCE destination therapy study."

Investor Breakout Session and Webcast

Following conclusion of presentations during the week at ISHLT, HeartWare management will host an investor breakout session, which will be available via audio webcast, at 7:00 pm Pacific (10:00 pm ET) on Friday, April 15, 2011.  Management will be joined by Dr. Slaughter, as well as Professor Thomas Krabatsch, M.D., Ph.D., Department of Cardiothoracic and Vascular Surgery, Deutsches Herzzentrum Berlin.

The audio from the meeting will be available to the public via webcast through the Company's website at (www.heartware.com) by selecting "ISHLT Investor Meeting" under the section titled "Corporate Presentations" on the home page.  A replay of the audio webcast will be available through the above weblink shortly following completion of the investor meeting.

The audio for the meeting may also be accessed by dialing 1-877-941-2068 five minutes prior to the scheduled start time and referencing "HeartWare."  For callers outside the United States, please dial +1-480-629-9712.  

About HeartWare International

HeartWare International develops and manufactures miniaturized implantable heart pumps, or ventricular assist devices, to treat Class IIIB / IV patients suffering from advanced heart failure.  The HeartWare® Ventricular Assist System features the HVAD® pump, a small full-output circulatory support device (up to 10L/min flow) designed to be implanted next to the heart, avoiding the abdominal surgery generally required to implant competing devices.  HeartWare has received CE Marking for the HeartWare System in the European Union and TGA approval in Australia.  The device is currently the subject of United States clinical trials for two indications: bridge-t
'/>"/>

SOURCE HeartWare International, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Presentation of HeartWare Clinical Results
2. HeartWare International Clinical Trial Shows 90% Survival at 180 Days
3. U.S. FDA Authorizes Expansion to 40 Clinical Sites for HeartWare U.S. Bridge-to-Transplant Clinical Trial
4. HeartWare International Reports Third Quarter Revenues of $7.5 Million
5. HeartWare to Present at 21st Annual Piper Jaffray Health Care Conference in New York City
6. HeartWare to Present at the UBS 2010 Global Life Sciences Conference
7. HeartWare to Present at Lazard Capital Markets Circulatory Assist Device Day
8. HeartWare to Report Financial Results for Third Quarter of 2010
9. HeartWare International Reports Third Quarter 2010 Revenues of $13.8 Million; Compared to $7.5 Million in Third Quarter of 2009
10. HeartWare Bridge-to-Transplant Data Featured as Late Breaking Clinical Trial at American Heart Association Scientific Sessions 2010
11. HeartWare to Present at the Lazard Capital Markets 7th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... 22, 2014 Apnea Sciences ( www.apneasciences.com ) ... Aliso Viejo , California.  Jimmy ... tremendous growth and worldwide expansion, a new facility with ... the anti snore cure have exceeded our expectations and ... are now in 23 countries and will be increasing ...
(Date:12/22/2014)...   TRU-D SmartUVC LLC, producers of the ... today that the General Services Administration has awarded the ... This newly formed agreement will allow TRU-D ... purchasers, including Department of Veteran Affairs and Department of ... purchasing solutions for the Ebola effort in ...
(Date:12/22/2014)... 2014  ConvaTec, a privately-held medical products and technologies ... Interim Chief Executive Officer of the company, effective December ... Berger .  "The Board of Directors of ConvaTec thanks ... the past three years," said Magnus Lundberg , ... confident that the company is well positioned for the ...
Breaking Medicine Technology:TRU-D SmartUVC LLC Awarded General Services Administration Contract to Expand Government Customer Base 2ConvaTec Names Paul Moraviec Interim CEO Effective December 22, 2014 2
... Dimes Publishes Findings in Nature Medicine, WHITE PLAINS, ... study of pre-eclampsia, a serious and potentially deadly,disorder that ... in mice that may have important implications for diagnosis,and ... Rodney E. Kellems, Ph.D., Department of,Biochemistry and Molecular Biology; ...
... NEW YORK, July 28 Polyphenon Pharma, an ... and,Drug Administration (FDA) has granted Orphan Drug Designation ... of chronic lymphocytic,leukemia (CLL). A Phase II study ... Minnesota where researchers are studying the effects of ...
Cached Medicine Technology:New Research on Pre-Eclampsia in Mice May Have Important Implications for Humans 2Polyphenon Pharma Receives Orphan Drug Designation for Its Botanical Drug, Polyphenon E, for the Treatment of CLL 2
(Date:12/21/2014)... By Dennis Thompson ... -- Former tobacco smokers find e-cigarettes less addictive than traditional ... e-cigarettes as often as they did regular cigarettes, thousands of ... to feel impulsive and irritable over their need to smoke, ... clear. The score was significantly less for e-cig use than ...
(Date:12/21/2014)... 2014 The number of Mirena lawsuits ... litigation underway in New Jersey, Bernstein Liebhard LLP reports. ... claims involving the birth control IUD have now been ... filed by women who allege spontaneous migration of the ... perforations and other complications they were inadequately warned about ...
(Date:12/21/2014)... (PRWEB) December 21, 2014 Serious Buyer, ... for Vintage 1967 Jm Morrison and the Doors International Ballroom ... This would also be the only time that Morrison's ... was on Nov. 25, 1967. According to Hawley, “This ... They did play the Alexandria Roller Rink earlier that ...
(Date:12/21/2014)... CA (PRWEB) December 21, 2014 Over ... resolved performance issues in hundreds of emergency departments across ... satisfaction. Its findings have been translated into an innovative ... leaders to correct deficiencies and enhance the patient experience. ... outsourced emergency physician staffing and management services for hospitals, ...
(Date:12/21/2014)... December 21, 2014 Theme ... a new intro plugin for Final Cut Pro X ... videos, logos, and more with absolute ease.” Said Christiana ... users the tools needed to easily animate their media ... Cut Pro X users to animate pictures, videos, logos, ...
Breaking Medicine News(10 mins):Health News:E-Cigarettes Less Addictive Than Regular Cigarettes, Study Finds 2Health News:E-Cigarettes Less Addictive Than Regular Cigarettes, Study Finds 3Health News:Mirena Lawsuits Approach 1,400 in Bergen County Litigation, Bernstein Liebhard LLP Reports 2Health News:Mirena Lawsuits Approach 1,400 in Bergen County Litigation, Bernstein Liebhard LLP Reports 3Health News:NES Health Launches Stipend Program for Emergency Physicians in Training to Financially Assist Emergency Department Doctors While They Learn 2Health News:Announcing a new plugin for Final Cut Pro X ProMotion from Pixel Film Studios. 2
... Lvov, a chemistry professor in Louisiana Techs Institute for ... the Year, beating candidates from Princeton University and companies ... in the journals January 2008 issue. , Lvov received ... cancer drugs. His research pioneers drug reformulation through polyelectrolyte ...
... YORK, Dec. 5 At a briefing ... vice president -- DuPont,Performance Materials, discussed the ... $6 billion in annual sales, the DuPont,Performance ... value-added applications development for the global,packaging, transportation, ...
... event of its kind in the country, provides ... healing and other resources, ... District, is hosting the fourth,Breaking The Silence 2007: A Summit on ... - 8 p.m. and Saturday,December 8, 8 a.m. - 3 p.m. ...
... Protalix,BioTherapeutics, Inc. (Amex: PLX ), announced today ... Jane H. Hsiao, Ph.D., have resigned from,the Company,s ... reasons. Dr. Hsiao was a member of the ... Protalix BioTherapeutics, Inc., Protalix is a biopharmaceutical ...
... As companies transform their,call centers into service-to-sales operations, ... while maintaining a customer service,function. Because they play ... is one of the key factors behind a ... leaders recommend reducing spans of control by as,much ...
... Resources to Coordinate Care, NEWTON, Mass., Dec. ... as a major cause of stress and functional ... in America are in a,silent crisis; overwhelmed by ... or elderly family member. These families face a,multitude ...
Cached Medicine News:Health News:Louisiana Tech professor is Small Times' Innovator of the Year 2Health News:DuPont Group Vice President Briefs Investors on Performance Materials Segment 2Health News:Actress Jenifer Lewis, Authors Dr. Michael Eric Dyson and Susan Taylor Among Featured Speakers for Senator Hughes' Behavioral Mental Health Summit 2Health News:Protalix BioTherapeutics Announces Resignation of Board Members 2Health News:Managing the Service-to-Sales Cultural Transformation - Complimentary Excerpt Available from Best Practices 2Health News:Family Caregivers in Crisis Have New Hope 2
Fine 3.0 mm platformed angled 60 degrees 10 mm from angle to tip. Serrated handle with dull finish....
Tennant straight tying forceps, 6.0 mm tying platforms, with pin, extra delicate smooth jaws....
Sinskey tying forceps, straight, fine, 7 mm tying platforms....
O'Gawa-Castroviejo tying forceps, straight shafts, 6 mm tying platforms, wide handle....
Medicine Products: